Literature DB >> 18045962

Growth inhibition of human salivary gland tumor cells by introduction of progesterone (Pg) receptor and Pg treatment.

T Yoshimura1, T Sumida, S Liu, A Onishi, S Shintani, P-Y Desprez, H Hamakawa.   

Abstract

Cancer of the salivary gland is one of the common cancers in the head and the neck regions. This type of cancer develops in the minor and the major salivary glands, and it sometimes metastasizes to other organs, particularly the lung. Morphologic mimicry and similarity in the expression of steroid hormone receptors between salivary gland tumors (SGTs) and breast tumors are well-known phenomena and are occasionally debated in the field of surgical pathology. Progesterone (Pg), one of the female sex steroid hormone, is intimately involved in the development of the mammary gland. Further, it is believed that Pg plays a role in breast cancer progression. However, little is known regarding its role in SGTs. In this study, we used ACCM, a human adenoid cystic carcinoma cell line established from the salivary gland, in order to clarify the role of the Pg receptor (PR) on cell proliferation. No effect of Pg on cell proliferation was observed in the PR-deficient aggressive ACCM cells. However, after introducing PR into the ACCM cells, Pg markedly inhibited the proliferative activity of the cells. This inhibitory effect on cell proliferation was accompanied by p21 upregulation, and Id1 and c-myc downregulation. Moreover, Pg-treated PR transfectants showed significant morphological change; they appeared more flattened and spread out when compared with the ethanol-treated control cells. Our results provided significant insights into the mechanism of suppression of the proliferative property of the cells via the function of PR, and suggested that PR reintroduction therapy might be a viable method of inhibiting human SGT progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18045962     DOI: 10.1677/erc.1.01253

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  7 in total

1.  Krüppel-like factor 4 mediates anti-proliferative effects of progesterone with G₀/G₁ arrest in human endometrial epithelial cells.

Authors:  Y Shimizu; T Takeuchi; S Mita; T Notsu; K Mizuguchi; S Kyo
Journal:  J Endocrinol Invest       Date:  2010-05-17       Impact factor: 4.256

2.  Suppression of invasion and metastasis in aggressive salivary cancer cells through targeted inhibition of ID1 gene expression.

Authors:  Ryuichi Murase; Tomoki Sumida; Rumi Kawamura; Akiko Onishi-Ishikawa; Hiroyuki Hamakawa; Sean D McAllister; Pierre-Yves Desprez
Journal:  Cancer Lett       Date:  2016-04-14       Impact factor: 8.679

Review 3.  Current update on established and novel biomarkers in salivary gland carcinoma pathology and the molecular pathways involved.

Authors:  Markus Stenner; J Peter Klussmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-12-04       Impact factor: 2.503

4.  Novel therapeutic strategies for malignant salivary gland tumors: lessons learned from breast cancer.

Authors:  Ryuichi Murase; Tomoki Sumida; Akiko Ishikawa; Rumi Murase; Sean D McAllister; Hiroyuki Hamakawa; Pierre-Yves Desprez
Journal:  Int J Otolaryngol       Date:  2011-11-21

Review 5.  Implications of telomeres and telomerase in endometrial pathology.

Authors:  D K Hapangama; A Kamal; G Saretzki
Journal:  Hum Reprod Update       Date:  2017-03-01       Impact factor: 15.610

6.  A Comparison of the Proteomic Expression in Pooled Saliva Specimens from Individuals Diagnosed with Ductal Carcinoma of the Breast with and without Lymph Node Involvement.

Authors:  Charles F Streckfus; Karen A Storthz; Lenora Bigler; William P Dubinsky
Journal:  J Oncol       Date:  2009-12-20       Impact factor: 4.375

7.  Targeting Id1 reduces proliferation and invasion in aggressive human salivary gland cancer cells.

Authors:  Tomoki Sumida; Ryuichi Murase; Akiko Onishi-Ishikawa; Sean D McAllister; Hiroyuki Hamakawa; Pierre-Yves Desprez
Journal:  BMC Cancer       Date:  2013-03-22       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.